The DOI matches its Crossref record; 82 of the 83 references it cites were found in a registry or an index.
Current and future treatments for Alzheimer's disease
Open accessAbstract
Alzheimer's dementia (AD) is increasingly being recognized as one of the most important medical and social problems in older people in industrialized and non-industrialized nations. To date, only symptomatic treatments exist for this disease, all trying to counterbalance the neurotransmitter disturbance. Three cholinesterase inhibitors (CIs) are currently available and have been approved for the treatment of mild to moderate AD. A further therapeutic option available for moderate to severe AD is memantine, an N-methyl-D-aspartate receptor noncompetitive antagonist. Treatments capable of stopping or at least effectively modifying the course of AD, referred to as 'disease-modifying' drugs, are still under extensive research. To block the progression of the disease they have to interfere with the pathogenic steps responsible for the clinical symptoms, including the deposition of extracellular amyloid β plaques and intracellular neurofibrillary tangle formation, inflammation, oxidative damage, iron deregulation and cholesterol metabolism. In this review we discuss current symptomatic treatments and new potential disease-modifying therapies for AD that are currently being studied in phase I-III trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“After the sequential breakdown of the big precursor protein amyloid precursor protein (APP) by the β- and γ-e -secretase, Aβ peptides with A38, A40, and A42 being the most prevalent forms are generated (Yiannopoulou et al., 2013).”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Yiannopoulou et al., 2013
In the citing paper
“Memantine is known to be a non-competitive NMDA receptor antagonist that counteracts the negative effects of high glutamate concentrations in the brain (Yiannopoulou et al., 2013).”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Yiannopoulou et al., 2013
In the citing paper
“The most efficient and prospective class is passive Ab immunotherapy using mAbs. The chief disadvantages of this class of medicines are cerebral microhemorrhages and vasogenic edema (Yiannopoulou et al., 2013).”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Yiannopoulou et al., 2013
In the citing paper
“Memantine is a noncompetitive low-affinity NMDA-receptor open-channel blocker and affects glutamatergic transmission.5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“AChEIs attempt at reducing the breakdown of acetylcholine levels in the brain of the patients with AD by inhibiting the responsible enzyme acetylcholinesterase in the synaptic cleft.5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“According to the “amyloid hypothesis” Aβ production in the brain initiates a cascade of events leading to the clinical syndrome of AD.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“The basic pathophysiology and neuropathology of AD that drives the current research suggests that the primary histopathologic lesions of AD are the extracellular amyloid plaques and the intracellular Tau neurofibrillary tangles (NFTs).5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“The elements of the cascade include local inflammation, oxidation, excitoxicity (excessive glutamate), and tau hyperphosphorylation.5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“The acetylocholinesterase inhibitors (AChEIs) which are approved for the treatment of AD are donepezil, galantamine, and rivastigmine.4,5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“It is the forming of amyloid oligomers to which neurotoxicity is mainly attributed and initiates the amyloid cascade.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Progressive neuronal destruction leads to shortage and imbalance between various neurotransmitters (eg, acetylcholine, dopamine, serotonin) and to the cognitive deficiencies seen in AD.5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“A further therapeutic agent approved for moderate to severe AD is the low-to-moderate affinity, noncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist memantine.4,5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“The APP cleavage by α-secretase leads to nonamyloidogenic pathway, whereas APP cleavage by β-secretase (BACE1) leads to amyloidogenic pathway.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“The Aβ derives from a protein overexpressed in AD, APP through sequential proteolysis by β-secretase (BACE1) in the extracellular domain and γ-secretase in the transmembrane region.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Sequential cleavage of APP by BACE1 in the extracellular and γ-secretase in the transmembrane area results in the Aβ production.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“The crucial step in AD pathogenesis is the production of amyloid (Aβ), which forms SPs (insoluble and proteolysis-resistant fibrils).”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Aβ40 is somewhat aggregation-prone and it is mostly found in the cerebral vasculature as a main component of “cerebral amyloid angiopathy.””
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Oligomers can form Aβ-fibrils that will eventually form amyloid plaques.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Major sites of γ-secretase cleavage usually occur in positions 40 and 42 of Aβ, thus Aβ40 and Aβ42 oligomers are the main products of the sequential APP cleavage, as the amyloidogenic pathway is favored in neurons because of the greater plentifulness of BACE1.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Aβ40 usually constitutes more than 50% of total detected Aβ.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Unluckily, concerning γ-secretase, in addition to APP, this particular enzyme acts on many other substances and cleaves different transmembrane proteins. Notch receptor 1, which is essential for control of normal cell differentiation and communication, is among them.5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Aβ42 is the most aggregation-prone form and has the tendency to cluster into oligomers.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Aβ38 is soluble, present in the vasculature of patients with sporadic and familial AD.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“On the contrary, the nonamyloidogenic processing is more favored in other cells without BACE1 predominance.5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Cerebral microhemorrhages and vasogenic edema are the main drawbacks in this group of agents.5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Abnormal accumulation or dyshomeostasis of metal ions such as iron, copper, and zinc has been associated with the pathophysiology of AD.5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
Global prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M. J., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K. S., Hasegawa, K., Hendrie, H. C., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,336
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869
Statins and the risk of dementia
Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S. S., & Drachman, D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03155-x · Cited by 1,764
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
McShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155
Clinical trial of indomethacin in Alzheimer's disease
Rogers, J., Kirby, L., Hempelman, S. R., Berry, D. A., McGeer, P. L., Kaszniak, A. W., Zalinski, J., Cofield, M., Mansukhani, L., Willson, P., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1609 · Cited by 991
Research works printed but not linked: 6
- Alva G., 2008, Psychiatry (Edgmont), 5, 27
- Ballard C., 2010, CNS Drugs, 24, 729
- Cummings J., 2008, Primary Psychiatry, 15, 66
- Hansen R., 2008, Clin Interv Aging, 3, 211
- Hey J., Koelsch G., Bilcer G., Jacobs A., Tolar M., Tang J. (2008) Single dose administration of the b-secretase inhibitor CTS21166 (ASP1720) reduces plasma Aβ40 in human subjects. Presented by Dr Koelsch in the International Conference on Alzheimer’s Disease (ICAD), Chicago, IL, USA, 26–31 July 2008. Available at: http://www.alzforum.org/new/detail.asp?id=1790
- Yiannopoulou K., 2009, Primary Psychiatry, 16, 29
Cited by
Sorted by citations
Items 101–200 of 682
Cellular senescence in Alzheimer’s disease: from physiology to pathology
Zhu, J., Wu, C., & Yang, L. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00447-4 · Cited by 74
Li, J., Maharjan, B., Xie, B., & Tao, C. (2020) · Journal of Medical Internet Research · doi:10.2196/19897 · Cited by 71
Zafeiris, D., Rutella, S., & Ball, G. (2018) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2018.02.001 · Cited by 66
Natural product-based pharmacological studies for neurological disorders
Puri, V., Kanojia, N., Sharma, A., Huanbutta, K., Dheer, D., & Sangnim, T. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1011740 · Cited by 72
Park, J.-C., Han, S.-H., Cho, H. J., Byun, M. S., Yi, D., Choe, Y. M., Kang, S., Jung, E. S., Won, S. J., Kim, E. H., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0248-8 · Cited by 63
Erdoğan, M., Kılıç, B., Sağkan, R. I., Aksakal, F., Erçeti̇n, T., Gülcan, H. O., & Doğruer, D. S. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113124 · Cited by 62
Lomartire, S., & Gonçalves, A. M. M. (2023) · Marine Drugs · doi:10.3390/md21050261 · Cited by 64
Hossain, M. F., Wang, N., Chen, R., Li, S., Roy, J., Uddin, M. G., Li, Z., Lim, L. W., & Song, Y. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101304 · Cited by 62
Semyachkina-Glushkovskaya, O. V., Postnov, D. E., Penzel, T., & Kurths, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176293 · Cited by 64
Brini, S., Sohrabi, H. R., Hébert, J. J., Forrest, M. R. L., Laine, M., Hämäläinen, H., Karrasch, M., Peiffer, J. J., Martins, R. N., & Fairchild, T. J. (2020) · Neuropsychology Review · doi:10.1007/s11065-020-09426-8 · Cited by 68
Limantoro, J., de Liyis, B. G., & Sutedja, J. C. (2023) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-023-00751-2 · Cited by 64
The Potential Benefits of Nanotechnology in Treating Alzheimer’s Disease
Ling, T. S., Chandrasegaran, S., Low, Z. X., Suan, T. L., Elaine, E., Nathan, D. V., Chai, Y. H., Gunasekaran, B., & Salvamani, S. (2021) · BioMed Research International · doi:10.1155/2021/5550938 · Cited by 61
Olasehinde, T. A., Mabinya, L. V., Olaniran, A. O., & Okoh, A. I. (2019) · Bioactive Carbohydrates and Dietary Fibre · doi:10.1016/j.bcdf.2019.100182 · Cited by 60
Metabolic disorder in Alzheimer’s disease
Poddar, M. K., Banerjee, S., Chakraborty, A., & Dutta, D. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00673-z · Cited by 58
Salazar, S. V., Gallardo, C., Kaufman, A. C., Herber, C. S., Haas, L. T., Robinson, S., Manson, J. C., Lee, M. K., & Strittmatter, S. M. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.0722-17.2017 · Cited by 55
Multi-Target-Directed Ligands as an Effective Strategy for the Treatment of Alzheimer’s Disease
Kumar, R., Kumar, V., Kumar, B., Thakur, A., & Dwivedi, A. R. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210512005508 · Cited by 55
Kamli, M. R., Sharaf, A. A. M., Sabir, J. S. M., & Rather, I. A. (2022) · Plants · doi:10.3390/plants11040514 · Cited by 55
Mandal, P. K., Roy, R. G., & Samkaria, A. (2022) · ACS Omega · doi:10.1021/acsomega.2c02760 · Cited by 56
Uddin, M. S., & Asaduzzaman, M. (2016) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000245 · Cited by 51
Saikia, J., Pandey, G., Sasidharan, S., Antony, F., Nemade, H. B., Kumar, S., Chaudhary, N., & Ramakrishnan, V. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00490 · Cited by 52
Muñoz, S. S., Engel, M., Balez, R., Do‐Ha, D., Cabral-da-Silva, M. C., Hernández, D., Berg, T., Fifita, J. A., Grima, N., Yang, S., et al. (2020) · Cells · doi:10.3390/cells9092018 · Cited by 49
Cruz-Vicente, P., Passarinha, L. A., Silvestre, S., & Gallardo, E. (2021) · Molecules · doi:10.3390/molecules26082193 · Cited by 52
The fate of interneurons, GABA A receptor sub‐types and perineuronal nets in Alzheimer's disease
Ali, A. B., Islam, A., & Constanti, A. (2022) · Brain Pathology · doi:10.1111/bpa.13129 · Cited by 49
Non-pharmacological cognitive intervention for aging and dementia: Current perspectives
Alves, J. (2013) · World Journal of Clinical Cases · doi:10.12998/wjcc.v1.i8.233 · Cited by 48
Editing the Central Nervous System Through CRISPR/Cas9 Systems
Cota-Coronado, A., Díaz-Martínez, N. F., Padilla‐Camberos, E., & Diaz-Martinez, N. E. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00110 · Cited by 51
Polyamine biomarkers as indicators of human disease
Amin, M., Tang, S., Shalamanova, L., Taylor, R. L., Wylie, S. R., Abdullah, B. M., & Whitehead, K. A. (2021) · Biomarkers · doi:10.1080/1354750x.2021.1875506 · Cited by 51
Barber, K., Mendonca, P., & Soliman, K. F. A. (2023) · Brain Sciences · doi:10.3390/brainsci13010145 · Cited by 51
Taheri, M. A., Torabi, S., Nabavi, N., & Semsarha, F. (2022) · ژورنال علمی کازمواینتل · doi:10.61450/joci.v1i2.18 · Cited by 46
Brain metabolism and Alzheimer's disease: The prospect of a metabolite-based therapy
Thomas, S. C., Alhasawi, A. A., Appanna, V. D., Auger, C., & Appanna, V. D. (2014) · The journal of nutrition health & aging · doi:10.1007/s12603-014-0511-7 · Cited by 51
Gažová, Z., Soukup, O., Šepsová, V., Šipošová, K., Drtinová, L., Jost, P., Špilovská, K., Korábečný, J., Nepovimová, E., Fedunová, D., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.11.020 · Cited by 47
Marine-Derived Compounds with Anti-Alzheimer’s Disease Activities
Ghoran, S. H., & Kijjoa, A. (2021) · Marine Drugs · doi:10.3390/md19080410 · Cited by 51
Deora, G. S., Kantham, S., Chan, S., Dighe, S. N., Veliyath, S. K., McColl, G., Parat, M., McGeary, R. P., & Ross, B. P. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00229 · Cited by 46
Singh, N. K., & Garabadu, D. (2021) · Neurotoxicity Research · doi:10.1007/s12640-021-00410-5 · Cited by 45
RetractedEmerging vistas in theranostic medicine
Shetty, Y., Prabhu, P. S., & Prabhakar, B. R. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.12.068 · Cited by 45
Li, J., Ding, X., Zhang, R., Jiang, W., Sun, X., Xia, Z., Wang, X., Wu, E., Zhang, Y., & Hu, Y. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.06.042 · Cited by 45
Focused ultrasound as a novel strategy for Alzheimer disease therapeutics
Meng, Y., Volpini, M., Black, S. E., Lozano, A. M., Hynynen, K., & Lipsman, N. (2017) · Annals of Neurology · doi:10.1002/ana.24933 · Cited by 45
Zhou, X., Xiao, W., Su, Z., Cheng, J., Zheng, C., Zhang, Z., Wang, Y., Wang, L., Xu, B., Li, S., et al. (2018) · Journal of Proteome Research · doi:10.1021/acs.jproteome.8b00818 · Cited by 43
Mahdi, O., Chiroma, S. M., Baharuldin, M. T. H., Nor, N. H. M., Taib, C. N. M., Jagadeesan, S., Devi, S., & Moklas, M. A. M. (2021) · Biomedicines · doi:10.3390/biomedicines9091270 · Cited by 43
Sheng, J., Zhang, S., Wu, L., Kumar, G., Liao, Y., K., P. G., & Fan, H. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1019187 · Cited by 43
Bioactive Hydrogels (Bio‐ HyGs ): Emerging Trends in Drug Delivery and Wound Healing Applications
Thirumalaivasan, N., Kanagaraj, K., Nangan, S., Pothu, R., Rajendra, S. P., Karuppiah, P., & Boddula, R. (2025) · Polymers for Advanced Technologies · doi:10.1002/pat.70132 · Cited by 46
Adav, S. S., & Sze, S. K. (2020) · Aging and Disease · doi:10.14336/ad.2019.0604 · Cited by 44
Malta, S. M., Batista, L. L., Silva, H. C. G., Franco, R. R., Silva, M. H., Rodrigues, T. S., Correia, L. I. V., Martins, M. M., Venturini, G., Espíndola, F. S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-15297-1 · Cited by 47
Albornoz, E. A., Woodruff, T. M., & Gordon, R. (2018) · Experientia supplementum · doi:10.1007/978-3-319-89390-7_3 · Cited by 42
Behl, T., Kaur, I., Frățilă, O., Brata, R. D., & BUNGAU, S. G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207443 · Cited by 47
Margel, S., Skaat, H., Corem‐Salkmon, E., Grinberg, I., Last, D., Goez, D., & Mardor, Y. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s52833 · Cited by 43
Ahmad, A., Ullah, F., Sadiq, A., Ayaz, M., Jan, M. S., Shahid, M. M., Wadood, A., Mahmood, F., Rashid, U., Ullah, R., et al. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s237420 · Cited by 41
Lao, H., & Zhang, X. (2021) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2021.3113668 · Cited by 41
Exploitation of Marine Molecules to Manage Alzheimer’s Disease
Silva, M., Seijas, P., & Otero, P. (2021) · Marine Drugs · doi:10.3390/md19070373 · Cited by 45
Nagata, Y., Hirayama, A., Ikeda, S., Shirahata, A., Shoji, F., Maruyama, M., Kayano, M., Bundo, M., Hattori, K., Yoshida, S., et al. (2018) · Biomarker Research · doi:10.1186/s40364-018-0119-x · Cited by 42
Therapeutic Potential of Astrocyte Transplantation
Hastings, N., Kuan, W., Osborne, A., & Kotter, M. (2022) · Cell Transplantation · doi:10.1177/09636897221105499 · Cited by 39
The potential of memory enhancement through modulation of perineuronal nets
Duncan, J. A., Foster, R., & Kwok, J. C. F. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14672 · Cited by 41
Goodarzi, P., Payab, M., Alavi-Moghadam, S., Larijani, B. A., Rahim, F., Bana, N., Sarvari, M., Adibi, H., Heravani, N. F., Hadavandkhani, M., et al. (2019) · Cell and Tissue Banking · doi:10.1007/s10561-019-09773-8 · Cited by 38
Bullain, S., & Doody, R. S. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15023 · Cited by 40
Early-onset dementia: key issues using a relationship-centred care approach
Nwadiugwu, M. C. (2020) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2020-138517 · Cited by 42
Ortiz, J. E., Pigni, N. B., Andújar, S. A., Roitman, G., Suvire, F. D., Enriz, R. D., Tapia, A. A., Bastida, J., & Feresin, G. E. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b00785 · Cited by 37
Abd‐Nikfarjam, B., Dolati‐Somarin, A., Rahimi, V. B., & Askari, V. R. (2023) · BioFactors · doi:10.1002/biof.1936 · Cited by 37
Challenges of Repurposing Tetracyclines for the Treatment of Alzheimer’s and Parkinson’s Disease
Markulin, I., Matasin, M., Turk, V. E., & Salković-Petrisic, M. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-021-02457-2 · Cited by 36
Budgett, R. F., Bakker, G., Sergeev, E., Bennett, K. A., & Bradley, S. J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.893422 · Cited by 38
Tau‐targeting nanoparticles for treatment of Alzheimer's disease
Pawar, S., Rauf, M. A., Abdelhady, H. G., & Iyer, A. K. (2024) · Exploration · doi:10.1002/exp.20230137 · Cited by 42
Lon, H., Mendonça, N., Goss, S. L., Othman, M. I. A., Locke, C. S., Jin, Z., & Rendenbach‐Mueller, B. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.598 · Cited by 36
Early Stage Glycosylation Biomarkers in Alzheimer’s Disease
Regan, P., McClean, P. L., Smyth, T. J., & Doherty, M. (2019) · Medicines · doi:10.3390/medicines6030092 · Cited by 38
Unraveling Alzheimer’s: the promise of aducanumab, lecanemab, and donanemab
Ameen, T. B., Kashif, S. N., Abbas, S. M. I., Babar, K., Ali, S. M. S., & Raheem, A. (2024) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-024-00845-5 · Cited by 43
Recent Progress in Nanomedicine for the Diagnosis and Treatment of Alzheimer’s Diseases
Yang, H., Tan, H., Wen, H., Xin, P., Liu, Y., Deng, Z., Xu, Y., Gao, F., Zhang, L., Ye, Z., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c11966 · Cited by 37
Jamal, S., Goyal, S., Shanker, A., & Grover, A. (2016) · BMC Genomics · doi:10.1186/s12864-016-3108-1 · Cited by 34
Zhou, X., Wang, L. Y., Xiao, W., Su, Z., Zheng, C., Zhang, Z., Wang, Y., Xu, B., Yang, X., & Hoi, M. P. M. (2019) · Experimental Neurobiology · doi:10.5607/en.2019.28.3.390 · Cited by 36
To protect or adversely affect? The dichotomous role of the NLRP1 inflammasome in human disease
Tupik, J. D., Nagai-Singer, M. A., & Allen, I. C. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100858 · Cited by 35
Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases
Liu, J., Ting, J. P., Al-Azzam, S., Ding, Y., & Afshar, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062805 · Cited by 37
Tran, S., Kuruppu, S., & Rajapakse, N. W. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215231 · Cited by 35
Shin, S. J., Jeong, Y.-O., Jeon, S. G., Kim, S., Lee, S.-K., Choi, H. S., Im, C. S., Kim, S. H., Kim, S. H., Park, J. H., et al. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.10.003 · Cited by 35
Current and Emerging Pharmacological Targets for the Treatment of Alzheimer’s Disease
Morsy, A., & Trippier, P. C. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190744 · Cited by 36
Photobiomodulation Therapy Attenuates Anxious-Depressive-Like Behavior in the TgF344 Rat Model
Yang, L., Wu, C., Tucker, L. D., Dong, Y., Li, Y., Xu, P., & Zhang, Q. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201616 · Cited by 34
Kumaran, K. R., Yunusa, S., Perimal, E. K., Wahab, H. A., Müller, C. P., & Hassan, Z. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220666 · Cited by 39
Li, W., Xu, L., Wang, S., Wang, Y., Pan, Y., Shi, L., & Guo, D. (2024) · Advanced Materials · doi:10.1002/adma.202401918 · Cited by 35
Baviskar, P. S., & Mahajan, H. S. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102990 · Cited by 36
Pugazhendhi, A., Shafreen, R. B., Devi, K. P., & Suganthy, N. (2018) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2018.02.081 · Cited by 33
Non-invasive Brain Delivery and Efficacy of BDNF in APP/PS1 Transgenic Mice
Kopec, B. M., Zhao, L., Rosa‐Molinar, E., & Siahaan, T. J. (2020) · Medical Research Archives · doi:10.18103/mra.v8i2.2043 · Cited by 35
Aran, K. R., Gupta, G. D., & Singh, S. (2021) · Inflammopharmacology · doi:10.1007/s10787-021-00883-y · Cited by 33
Therapies for human prion diseases.
Panegyres, P. K., & Armari, E. (2013) · Europe PMC (PubMed Central) · Cited by 33
Akter, S., Liu, Z., Simões, E. J., & Rao, P. R. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100169 · Cited by 37
Blaikie, L., Kay, G., & Lin, P. K. T. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127505 · Cited by 33
Zhao, H., Cui, S., Yu, Q., Liu, Y., Cui, X., Hu, X., Kurban, N., Li, M.-Y., Li, Z., Xu, J., et al. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113725 · Cited by 32
Janaszewska, A., Klajnert‐Maculewicz, B., Marcinkowska, M., Duchnowicz, P., Appelhans, D., Grasso, G., Deriu, M. A., Danani, A., Cangiotti, M., & Ottaviani, M. F. (2017) · Nano Research · doi:10.1007/s12274-017-1734-9 · Cited by 32
Nanotechnology in the diagnostic and therapy for Alzheimer's disease
Panghal, A., & Flora, S. J. S. (2024) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2024.130559 · Cited by 31
Lu, Y., Liu, Q., & Yu, Q. (2018) · Europe PMC (PubMed Central) · Cited by 31
Elucidating the Effect of Static Electric Field on Amyloid Beta 1–42 Supramolecular Assembly
Muscat, S., Stojceski, F., & Danani, A. (2020) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2020.107535 · Cited by 32
Alghazwi, M., Charoensiddhi, S., Smid, S. D., & Zhang, W. Y. (2020) · Journal of Functional Foods · doi:10.1016/j.jff.2020.103893 · Cited by 31
Syndecan-3 as a Novel Biomarker in Alzheimer’s Disease
Hudák, A., Letoha, A., Vízler, C., & Letoha, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063407 · Cited by 32
The Role of Heme and Copper in Alzheimer’s Disease and Type 2 Diabetes Mellitus
Pal, I., & Dey, S. G. (2023) · JACS Au · doi:10.1021/jacsau.2c00572 · Cited by 32
Dave, B. P., Shah, Y. B., Maheshwari, K. G., Mansuri, M. K. A., Prajapati, B., Postwala, H. I., & Chorawala, M. R. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01408-7 · Cited by 33
Špilovská, K., Korábečný, J., Horova, A., Musílek, K., Nepovimová, E., Drtinová, L., Gažová, Z., Šipošová, K., Doležal, R., Jun, D., et al. (2015) · Medicinal Chemistry Research · doi:10.1007/s00044-015-1316-x · Cited by 31
Low, L., Carroll, S., Merom, D., Baker, J. R., Kochan, N. A., Moran, F., & Brodaty, H. (2016) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2016.09.005 · Cited by 30
Aging‐ and vascular‐related pathologies
Wen, S., & Wong, C. H. Y. (2018) · Microcirculation · doi:10.1111/micc.12463 · Cited by 31
A Therapeutic Strategy for Alzheimer's Disease Focused on Immune-inflammatory Modulation
Kim, S. H., Noh, M., Kim, H.-J., Oh, K., Park, J., Lee, S.-G., Moon, Y., Kim, Y.-E., Bae, J. S., Jin, H. K., et al. (2019) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2019.18.2.33 · Cited by 30
Nose to Brain Delivery of Nanocarriers Towards Attenuation of Demented Condition
Gorain, B., Rajeswary, D. C., Pandey, M., Kesharwani, P., Kumbhar, S. A., & Choudhury, H. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200313125613 · Cited by 31
Minta, K., Brinkmalm, G., Portelius, E., Johansson, P., Svensson, J., Kettunen, P., Wallin, A., Zetterberg, H., Blennow, K., & Andréasson, U. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-201039 · Cited by 32
Sivamaruthi, B. S., Kapoor, D. U., Kukkar, R. R., Gaur, M., Elossaily, G. M., Prajapati, B. G., & Chaiyasut, C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15122666 · Cited by 29
Flavonoids and Alzheimer’s disease: reviewing the evidence for neuroprotective potential
Amin, M. A., Dehbia, Z., Nafady, M. H., Zehravi, M., Kumar, K. P., Haque, M. A., Baig, M. S., Farhana, A., Khan, S. L., Afroz, T., et al. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04922-w · Cited by 29
Paul, K., Ganguly, U., Chakrabarti, S., & Bhattacharjee, P. (2019) · NeuroMolecular Medicine · doi:10.1007/s12017-019-08574-2 · Cited by 30
Epidemiology and Risk Factors of Alzheimer’s disease in Iran: A Systematic Review
Navipour, E., Neamatshahi, M., Barabadi, Z., Neamatshahi, M., & Keykhosravi, A. (2020) · Iranian Journal of Public Health · doi:10.18502/ijph.v48i12.3544 · Cited by 31
Cell and Tissue Instructive Materials for Central Nervous System Repair
Rocha, L. A., Silva, D., Barata‐Antunes, S., Cavaleiro, H., Gomes, E. D., Silva, N. A., & Salgado, A. J. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201909083 · Cited by 31
Metadata
- Authors
- Yiannopoulou, K. G., & Papageorgiou, S. G.
- Affiliations
- Laiko General Hospital of Athens (GR)
- National and Kapodistrian University of Athens (GR)
- Venue
- Therapeutic Advances in Neurological Disorders
- Publisher
- SAGE Publications
- Published
- 2012-10-15
- Volume
- 6
- Issue
- 1
- Pages
- 19-33
- ISSN
- 1756-2856 (ISSN-L)
- 1756-2864
- PMC
- PMC3526946
- OpenAlex
- W1987204546
- Cited by
- 677
- References
- 83
- Citations by year
- 2026: 35 · 2025: 55 · 2024: 66 · 2023: 70 · 2022: 84 · 2021: 81 · 2020: 83 · 2019: 61 · 2018: 45 · 2017: 37 · 2016: 27 · 2015: 9 · 2014: 9 · 2013: 14
- FWCI
- 6.86
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Therapeutic Advances in Neurological Disorders (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, cholinesterase inhibitors, memantine, disease-modifying therapy, symptomatic treatment, amyloid plaques, neurofibrillary tangles, oxidative stress, neuroinflammation, cholesterol metabolism, NMDA receptor antagonists, clinical trials
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
